First human trials at Rutgers Health and other institutions demonstrate better infection resistance and limb preservation than synthetic grafts.

Enzyvant is only the second company to announce a RMAT designation for an investigational drug – the first being Humacyte’s Humacyl ... processes to harvest, culture, and apply allogeneic ...

This week on Polygon, we’re looking at how cultural differences affect media in a special issue called Culture Shock. From text localization to character design, religious considerations to ...

Humacyte, Inc. (NASDAQ:HUMA – Free Report) – Cantor Fitzgerald upped their FY2024 EPS estimates for Humacyte in a research note issued on Wednesday, January 15th. Cantor Fitzgerald analyst K.

Humacyte (HUMA) announced an update of plans for the commercial launch of Symvess for extremity arterial injury. Humacyte is responding to requests for quotations from hospitals and has initiated ...

DURHAM, N.C., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a biotechnology platform company developing universally implantable, bioengineered ...

Shares of HUMA opened at $4.61 on Monday. The company’s 50 day simple moving average is $4.67 and its 200-day simple moving average is $5.69. Humacyte has a 12-month low of $2.48 and a 12-month ...

Humacyte is responding to requests for quotations from hospitals and has initiated the Value Analysis Committee approval processes at multiple hospitals as part of the preparation for market launch.

If one thing distinguishes companies that consistently achieve the best results over time, it is their culture. According to a study published by Deloitte, companies with inclusive, supportive ...

The Euronews Culture team has selected its People of the Year, both European and Global, in the fields of cinema, music, arts, literature, fashion and sport. We spent several weeks weighing ...

LOS ANGELES, Jan. 17, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Humacyte, Inc. ("HUMA" or "the Company") (NASDAQ: HUMA) for violations of the ...